Well-documented racial differences in drug response1- 3
have led to considerable debate about "racial profiling" of pharmacotherapy.4,5 Still, it is argued that race is a biologically meaningless term,4
and an understanding of physiology and the genetic underpinnings of drug response
is a better way to target therapy. Furthermore, an individualized approach
to pharmacotherapy with monitoring of patient response and modification of
therapy as necessary might be just as effective as race-guided therapy. Whether
to consider race in drug therapy has important implications for physicians,
drug developers, and regulators. In this issue of THE JOURNAL, Ahluwalia and
colleagues6 present the results of a clinical
trial of sustained-release bupropion hydrochloride (bupropion SR) to aid smoking
cessation in African American smokers treated at an inner-city community health
center. The study demonstrates efficacy of bupropion, but the study design
and resultant data raise questions about the ultimate value of pharmacotherapy
trials in racial and economic subgroups.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 23
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.